Mitochondria as new therapeutic targets for eradicating cancer stem cells: Quantitative proteomics and functional validation via MCT1/2 inhibition

Oncotarget

Volumn 5, Issue 22, 2014, Pages 11029-11037

  Lamb, Rebecca ^a,b   Harrison, Hannah ^a,b   Hulit, James ^a,b   Smith, Duncan L ^c   Lisanti, Michael P ^a,b   Sotgia, Federica ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Cancer stem cells; Ketone metabolism; Mitochondrial markers; Monocarboxylate transporters; Proteomic analysis

Indexed keywords

KETONE BODY; LACTIC ACID; MITOCHONDRIAL ATP SYNTHASE; MONOCARBOXYLATE TRANSPORTER 1; MONOCARBOXYLATE TRANSPORTER 2; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; UNCLASSIFIED DRUG; AR C155858; COTRANSPORTER; MITOCHONDRIAL PROTEIN; MONOCARBOXYLATE TRANSPORT PROTEIN 1; MONOCARBOXYLATE TRANSPORTER; SLC16A7 PROTEIN, HUMAN; THIOPHENE DERIVATIVE; URACIL;

AEROBIC METABOLISM; ARTICLE; BIOGENESIS; CANCER STEM CELL; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; ENZYME INHIBITION; MCF 7 CELL LINE; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; MITOPHAGY; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS; VALIDATION STUDY; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; GENETICS; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES; PROTEOMICS; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; MCF-7 CELLS; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; MOLECULAR TARGETED THERAPY; MONOCARBOXYLIC ACID TRANSPORTERS; NEOPLASTIC STEM CELLS; PROTEOMICS; SYMPORTERS; THIOPHENES; URACIL;

EID: 84917706145     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2789     Document Type: Article

References (24)

1. Zhang M and Rosen JM. Stem cells in the etiology and treatment of cancer. Curr Opin Genet Dev. 2006; 16(1):60-64.
2. Chandler JM and Lagasse E. Cancerous stem cells: deviant stem cells with cancer-causing misbehavior. Stem Cell Res Ther. 2010; 1(2):13.
3. Scopelliti A, Cammareri P, Catalano V, Saladino V, Todaro M and Stassi G. Therapeutic implications of Cancer Initiating Cells. Expert Opin Biol Ther. 2009; 9(8):1005-1016.
4. Duggal R, Minev B, Geissinger U, Wang H, Chen NG, Koka PS and Szalay AA. Biotherapeutic approaches to target cancer stem cells. J Stem Cells. 2013; 8(3-4):135-149.
5. Shaw FL, Harrison H, Spence K, Ablett MP, Simoes BM, Farnie G and Clarke RB. A detailed mammosphere assay protocol for the quantification of breast stem cell activity. J Mammary Gland Biol Neoplasia. 2012; 17(2):111-117.
6. Borodkina A, Shatrova A, Abushik P, Nikolsky N and Burova E. Interaction between ROS dependent DNA damage, mitochondria and p38 MAPK underlies senescence of human adult stem cells. Aging (Albany NY). 2014; 6(6):481-495.
7. Marcinek DJ and Siegel MP. Targeting redox biology to reverse mitochondrial dysfunction. Aging (Albany NY). 2013; 5(8):588-589.
8. Yoon MJ, Lee AR, Jeong SA, Kim YS, Kim JY, Kwon YJ and Choi KS. Release of Ca2+ from the endoplasmic reticulum and its subsequent influx into mitochondria trigger celastrol-induced paraptosis in cancer cells. Oncotarget. 2014; 5(16):6816-6831.
9. Corazao-Rozas P, Guerreschi P, Jendoubi M, Andre F, Jonneaux A, Scalbert C, Garcon G, Malet-Martino M, Balayssac S, Rocchi S, Savina A, Formstecher P, Mortier L, Kluza J and Marchetti P. Mitochondrial oxidative stress is the Achille's heel of melanoma cells resistant to Brafmutant inhibitor. Oncotarget. 2013; 4(11):1986-1998.
10. Hall A, Meyle KD, Lange MK, Klima M, Sanderhoff M, Dahl C, Abildgaard C, Thorup K, Moghimi SM, Jensen PB, Bartek J, Guldberg P and Christensen C. Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the (V600E)BRAF oncogene. Oncotarget. 2013; 4(4):584-599.
11. Muppani N, Nyman U and Joseph B. TAp73alpha protects small cell lung carcinoma cells from caspase-2 induced mitochondrial mediated apoptotic cell death. Oncotarget. 2011; 2(12):1145-1154.
12. Francipane MG and Lagasse E. Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1. Oncotarget. 2013; 4(11):1948-1962.
13. Cufi S, Corominas-Faja B, Vazquez-Martin A, Oliveras-Ferraros C, Dorca J, Bosch-Barrera J, Martin-Castillo B and Menendez JA. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts. Oncotarget. 2012; 3(4):395-398.
14. Ovens MJ, Manoharan C, Wilson MC, Murray CM and Halestrap AP. The inhibition of monocarboxylate transporter 2 (MCT2) by AR-C155858 is modulated by the associated ancillary protein. Biochem J. 2010; 431(2):217-225.
15. Ovens MJ, Davies AJ, Wilson MC, Murray CM and Halestrap AP. AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7-10. Biochem J. 2010; 425(3):523-530.
16. Draoui N, Schicke O, Seront E, Bouzin C, Sonveaux P, Riant O and Feron O. Antitumor activity of 7-aminocarboxycoumarin derivatives, a new class of potent inhibitors of lactate influx but not efflux. Mol Cancer Ther. 2014; 13(6):1410-1418.
17. Casey T, Bond J, Tighe S, Hunter T, Lintault L, Patel O, Eneman J, Crocker A, White J, Tessitore J, Stanley M, Harlow S, Weaver D, Muss H and Plaut K. Molecular signatures suggest a major role for stromal cells in development of invasive breast cancer. Breast Cancer Res Treat. 2009; 114(1):47-62.
18. Curry JM, Tuluc M, Whitaker-Menezes D, Ames JA, Anantharaman A, Butera A, Leiby B, Cognetti DM, Sotgia F, Lisanti MP and Martinez-Outschoorn UE. Cancer metabolism, stemness and tumor recurrence: MCT1 and MCT4 are functional biomarkers of metabolic symbiosis in head and neck cancer. Cell Cycle. 2013; 12(9):1371-1384.
19. Martinez-Outschoorn UE, Prisco M, Ertel A, Tsirigos A, Lin Z, Pavlides S, Wang C, Flomenberg N, Knudsen ES, Howell A, Pestell RG, Sotgia F and Lisanti MP. Ketones and lactate increase cancer cell "stemness," driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via Metabolo-Genomics. Cell Cycle. 2011; 10(8):1271-1286.
20. Cuyas E, Corominas-Faja B and Menendez JA. The nutritional phenome of EMT-induced cancer stem-like cells. Oncotarget. 2014; 5(12):3970-3982.
21. Aras S, Bai M, Lee I, Springett R, Huttemann M and Grossman LI. MNRR1 (formerly CHCHD2) is a biorganellar regulator of mitochondrial metabolism. Mitochondrion. 2014.
22. Aras S, Pak O, Sommer N, Finley R, Jr., Huttemann M, Weissmann N and Grossman LI. Oxygen-dependent expression of cytochrome c oxidase subunit 4-2 gene expression is mediated by transcription factors RBPJ, CXXC5 and CHCHD2. Nucleic Acids Res. 2013; 41(4):2255-2266.
23. Seo M, Lee WH and Suk K. Identification of novel cell migration-promoting genes by a functional genetic screen. Faseb J. 2010; 24(2):464-478.
24. Holland M, Castro FV, Alexander S, Smith D, Liu J, Walker M, Bitton D, Mulryan K, Ashton G, Blaylock M, Bagley S, Connolly Y, Bridgeman J, Miller C, Krishnan S, Dempsey C, et al. RAC2, AEP, and ICAM1 expression are associated with CNS disease in a mouse model of pre-B childhood acute lymphoblastic leukemia. Blood. 2011; 118(3):638-649.